SET Biotechnology Practice Test 3

21. The CYP enzyme primarily responsible for metabolizing approximately 50% of clinically used drugs:

A) CYP1A2 B) CYP2C9 C) CYP2D6 D) CYP3A4

22. The purpose of the CPIC guidelines is:

A) Standardise pharmacogenomics testing B) Interpret genetic variants C) Provide genotype-based dosage recommendations D) Predict drug efficacy

23. The compound that appears identical to an active drug but having no biological activity:

A) Dummy drug B) Placebo C) Peptidomemetic D) Gazebo

24. Which class of the following antibiotics targets ribosomal subunits?

A) Aminoglycosides B) Macrolides C) Tetracyclins D) Gentamycins

25. Identify the statement which best describes an induced fit:

A) The process by which a binding site alters shape such that it is ready to accept a drug B) The process by which binding of a drug to a binding site alters the shape of the binding site C) The process by which a drug adopts the correct binding conformation before entering a binding site D) The process by which a binding site alters the shape of the drug into the binding conformation before binding

26. The first recombinant vaccine produced by biotechnology targeted the surface antigen of:

A) Corona virus B) Ebola virus C) Hepatitis B virus D) DENV1

27. Which technique will you adopt for detection and quantification of cytokines in patient samples?

A) ELISPOT B) Cytometric bead assay C) Immuno precipitation D) Western blot

28. The mechanism of action of the Mabalemtuzumab in multiple sclerosis:

A) Blocks CD52 on B &T cells B) Inhibits TNF-alpha C) Depletes CD20 +ve B cells D) Blocks VLA-4

29. The most commonly used monoclonal antibody for treatment of breast cancer:

A) Imdevimab B) Casirivimab C) Erbutir D) Herceptin

30. Which type of antagonism is characterised by a parallel shift of the agonist dose response curve?

A) Competitive B) Non-competitive C) Uncompetitive D) Mixed